Loading...
Identifying patients with Alzheimer disease (AD) who would be most appropriate for anti-amyloid immunotherapies is needed. To determine whether plasma biomarkers can help identify amyloid positivity and tau burden in patients seen at memory clinics for subjective cognitive decline, mild cognitive impairment, or dementia, investigators tested patients' plasma biomarkers, including phosphorylated tau 181 (p-tau181), p-tau217, p-tau231, N-terminal tau, glial fibrillary acidic protein, and neurofilament light chain. They also tested cerebrospinal fluid (CSF) levels of p-tau217, amyloid-beta 42 (Aβ42), and amyloid beta 40 (Aβ40) and obtained positron emission tomography (PET) imaging of Aβ and tau. Aβ positivity was based on a CSF Aβ42/40 ratio …